These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34040354)

  • 21. Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: a systematic review.
    Sawicka M; Tracy DK
    Ther Adv Psychopharmacol; 2017 Sep; 7(8-9):211-224. PubMed ID: 28959434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The relationship between dissociative symptoms and the medications used in the treatment of opioid use disorder.
    Gainer DM; Crawford TN; Fischer KB; Wright MD
    J Subst Abuse Treat; 2021 Feb; 121():108195. PubMed ID: 33357605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological treatment of alcohol dependence: a review of the evidence.
    Garbutt JC; West SL; Carey TS; Lohr KN; Crews FT
    JAMA; 1999 Apr; 281(14):1318-25. PubMed ID: 10208148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Opioid antagonists for alcohol dependence.
    Srisurapanont M; Jarusuraisin N
    Cochrane Database Syst Rev; 2002; (2):CD001867. PubMed ID: 12076425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
    Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
    J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive memantine for opioid use disorder treatment: A systematic review.
    Elias AM; Pepin MJ; Brown JN
    J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.
    Jarvis BP; Holtyn AF; Berry MS; Subramaniam S; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    J Subst Abuse Treat; 2018 Feb; 85():38-44. PubMed ID: 28449955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions.
    Connery HS
    Harv Rev Psychiatry; 2015; 23(2):63-75. PubMed ID: 25747920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naltrexone and buprenorphine combination in the treatment of opioid dependence.
    Gerra G; Fantoma A; Zaimovic A
    J Psychopharmacol; 2006 Nov; 20(6):806-14. PubMed ID: 16401652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
    Gaulen Z; Brenna IH; Fadnes LT; Šaltytė Benth J; Solli KK; Kunoe N; Opheim A; Tanum L
    Eur Addict Res; 2022; 28(1):56-67. PubMed ID: 34569487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-month outcomes.
    Dunn K; DeFulio A; Everly JJ; Donlin WD; Aklin WM; Nuzzo PA; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Psychol Addict Behav; 2015 Jun; 29(2):270-6. PubMed ID: 25134047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States.
    Hochheimer M; Unick GJ
    Addict Behav; 2022 Jan; 124():107113. PubMed ID: 34543869
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population.
    Walker JR; Korte JE; McRae-Clark AL; Hartwell KJ
    J Stud Alcohol Drugs; 2019 Sep; 80(5):572-577. PubMed ID: 31603760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
    Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
    Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
    Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
    Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of naltrexone for amfetamine and methamfetamine use disorder: a systematic review of randomized controlled trials.
    Lam L; Anand S; Li X; Tse ML; Zhao JX; Chan EW
    Clin Toxicol (Phila); 2019 Apr; 57(4):225-233. PubMed ID: 30451013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial.
    Solli KK; Latif ZE; Opheim A; Krajci P; Sharma-Haase K; Benth JŠ; Tanum L; Kunoe N
    Addiction; 2018 Oct; 113(10):1840-1849. PubMed ID: 29806872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
    Garbutt JC; Kranzler HR; O'Malley SS; Gastfriend DR; Pettinati HM; Silverman BL; Loewy JW; Ehrich EW;
    JAMA; 2005 Apr; 293(13):1617-25. PubMed ID: 15811981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opioid antagonists for smoking cessation.
    David S; Lancaster T; Stead LF
    Cochrane Database Syst Rev; 2001; (3):CD003086. PubMed ID: 11687036
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.